The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy

• Published in: Radiation oncology (London, England) Vol. 9; no. 1; p. 188
• Main Authors: Meng, Xiangjiao, Huang, Zhaoqin, Wang, Renben, Jiao, Yuhong, Li, Huijuan, Xu, Xiaoqing, Feng, Rui, Zhu, Kunli, Jiang, Shumei, Yan, Hongjiang, Yu, Jinming
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 27.08.2014; BioMed Central
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Aged; Biomarkers, Tumor - analysis; Biotechnology industry; Breast cancer; Cancer patients; Care and treatment; Chemoradiotherapy - methods; Chemotherapy; Colorectal cancer; Complications and side effects; Diagnosis; Disease-Free Survival; Enhancer of Zeste Homolog 2 Protein; Female; Genetic aspects; Health aspects; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Medical research; Medicine, Experimental; Middle Aged; Neoadjuvant Therapy - methods; NMR; Nuclear magnetic resonance; Patient outcomes; Polycomb Repressive Complex 2 - analysis; Polycomb Repressive Complex 2 - biosynthesis; Prognosis; Proportional Hazards Models; Rectal Neoplasms - mortality; Rectal Neoplasms - pathology; Rectal Neoplasms - therapy; Retrospective Studies; Rodents

Neoadjuvant chemoradiotherapy (nCRT) combined with surgery has been implemented as a standard treatment strategy in locally advanced rectal cancer (LARC). However, there is a wide spectrum of response to nCRT. The aim of this study was to determine whether enhancer of zeste homologue 2 (EZH2 ) expre...